908 Devices, a pioneer of analytical devices for chemical and biomolecular analysis, today announced an expansion of their joint innovation partnership with Transcenta, a fully integrated global biotherapeutics company. The company’s world-class technology center (“Center”) for biotherapeutic process and product development and manufacturing subsidiary, HJB, is located in Hangzhou, China.

908 Devices and Transcenta’s HJB subsidiary launched their partnership mid-2018. Since then, the ZipChip® system has been a critical part of the Center’s analytical toolset – streamlining internal processes and enabling rapid measurement of Critical Quality Attributes (CQAs), native proteins, and small molecules. Transcenta will now deploy 908 Devices’ Rebel™ system, a first of its kind analyzer for at-line cell culture media analysis, to accelerate their process development cycles and free up the capacity of their analytical lab.

“We value our partnership with 908 Devices and ZipChip has become our workhorse for large molecule and media component analyses. It provides the speed and higher resolution needed with mass spectrometry analysis and has helped us accelerate our CMC development. With the Rebel’s ultra-fast analysis of amino acids and vitamins in-house, we can now make real-time decisions to further accelerate our media development and optimization efforts and intensify our cell culture processes and push our continuous perfusion platform beyond our recently announced 4 g/L-day and advance our Integrated Continuous Bioprocessing (ICB) platform,” said Dr. Christopher Hwang, CTO of Transcenta.

“Transcenta leads the way in deploying state-of-the-art tools in their biologics discovery and development workflows. It’s exciting to take our collaboration into this next phase, and to see how ZipChip and Rebel can work in tandem to help drive that innovation,” said Dr. Kevin J. Knopp, CEO and Co-Founder of 908 Devices.